Sign in
CompletedNo phase

The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial

Key facts

Who runs it
Shanghai Eye Disease Prevention and Treatment Center
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
219 people enrolled
Started
4 Jul 2021
Ended
1 Sept 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atropine
Record updated
12 March 2026

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • At least one eye with cycloplegic optometric spherical equivalent of -5.00 to -10.00D and best corrected distant visual acuity of at least 0.5 and near visual acuity of at least 1.0, Titmus Stereo acuity ≤ 80 seconds, Vision with external occultation of ≤ 10 prismatic diopters , vision with internal occultation of ≤ 6-8 prismatic diopters, and astigmatism equal to or less than -2.50D
  • Myopia progression greater than 0.5D in the past year
  • Possess normal cognitive and verbal communication abilities to actively cooperate with the prescribed treatment
  • Written informed consent from the guardian and the child

Who cannot take part

  • Previous treatment with anticholinergics including atropine within the previous 1 year, or use of OK lenses, multifocal soft lenses within 3 months
  • Diseases of the study eye: keratitis, cone cornea, congenital cataract, glaucoma, fundus diseases; combined with inflammation of the anterior or posterior segment of the eye, such as acute conjunctivitis, iridocyclitis
  • Systemic diseases affecting the use of drugs: albinism, epilepsy, severe psychoneurological disorders, congenital heart disease, cardiac arrhythmias
  • Atropine allergy
  • Other conditions judged by the investigator to be unsuitable for participation in the trial
  • Very low birth weight less than 1500 g

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Objective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropine eye drops in myopia control.

Read full original descriptionShow less

Intervention: Group 1 (0.01% atropine group), Group 2 (0.04% atropine group), Group 3 (0.1% atropine group). During the 2-year intervention period after entering the group, each concentration of atropine eye drops were given every night at a fixed time before going to bed, one drop each time, implemented by parents (supervision), and the wechat small program was completed.

The 3 groups in the trial

  • Group 1Existing treatment, for comparison

    0.01% atropine

    Treatment: Atropine

  • Group 2Treatment being tested

    0.04% atropine

    Treatment: Atropine

  • Group 3Treatment being tested

    0.1% atropine

    Treatment: Atropine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Shanghai Eye Disease Prevention and Treatment Center
Publications
Record updated
12 March 2026